Alluvi, initially dubbed LY3414901, represents a significant advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable impact in early trial data, with substantial slimming ob